Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px
Document › Details

Adaptimmune Therapeutics plc. (5/10/17). "Press Release: Adaptimmune Reports First Quarter 2017 Financial Results". Philadeliphia, PA & Oxford.

Organisations Organisation Adaptimmune Therapeutics plc (Nasdaq: ADAP)
  Group Adaptimmune (Group)
  Organisation 2 Matrix Capital Management Company L.P.
Products Product AFP SPEAR™ T-cell therapy
  Product 2 NY-ESO SPEAR® T-cell therapy
Index term Index term Adaptimmune–Matrix Capital Management: investment, 201704 direct offering $42m of 7m ADSs at $6/ADS
Persons Person Noble, James (Adaptimmune CEO before MediGene 200609–200809 before Avidex)
  Person 2 Tayton-Martin, Helen (Adaptimmune 201703– CBO before COO + Co-Founder before Avidex/Medigene)
     


   
Record changed: 2017-05-28

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany iito 600x60px

More documents for Adaptimmune (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px




» top